Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity

Journal of Immunology

Volumn 173, Issue 11, 2004, Pages 7078-7089

  Devito, Claudia ^a   Zuber, Bartek ^a   Schröder, Ulf ^b   Benthin, Reinhold ^a   Okuda, Kenji ^c   Broliden, Kristina ^d   Wahren, Britta ^a   Hinkula, Jorma ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b Karolinska Science Park   (Sweden)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DNA VACCINE; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; FECES; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INTESTINE; LONG TERM CARE; LONG TERM EXPOSURE; LUNG; LYMPH NODE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; VAGINA;

EID: 9144244280     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.11.7078     Document Type: Article

References (61)

1. Vittinghoff, E., J. Douglas, F. Judson, D. McKirnan, K. MacQueen, and S. P Buchbinder. 1999. Per-contact risk of human immunodeficiency virus transmission between male and sexual partners. Am. J. Epidemiol. 150:306.
2. Gray, R. H., M. J. Wawer, R. Brookmeyer, N. K. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. VanCott, T. C. Quinn, et al. 2001. Probability of HIV transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 357:1149.
3. Norvell, M. K., G. I. Benrubi, and R. J. Thompson. 1984. Investigation of microtrauma after sexual intercourse. J. Reprod. Med. 29:269.
4. Stone, A. 2002. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 1:977.
5. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Exp. Opin. Invest. Drugs 11:1077.
6. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, et al. 1998. Potent suppression of HIV-1 replication in humans by T-20 a peptide inhibitor of gp 41-mediated virus entry. Nat. Med. 4:1302.
7. Baldwin, C. E., R. W. Sanders, and B. Berkhout. 2003. Inhibiting HIV-1 entry with fusion inhibitors. Curr. Med. Chem. 10:1773.
8. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA. Science 292:69.
9. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486.
10. + T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167:7180.
11. Kim, J. J., J. S. Yang, L. K. Nottingham, D. J. Lee, M. Lee, K. H. Manson, M. S. Wyand, J. D Boyer, R. E. Ugen, and D. B. Weiner. 2001. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization. Virology 285:204.
12. Eo, S. K., M. Gierynska, A. A. Kamar, and B. T. Rouse. 2001. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166:5473.
13. Hanke, T., V. C. Neumann, T. J. Blanchard, P. Sweeney, A. V. S. Hill, G. L. Smith, and A. McMichael. 1999. Effective induction of HIV-specific CTL by multiple-epitope using gene gun in a combined vaccination regimen. Vaccine 17:589.
14. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207.
15. Mascola, J. R., M. G. Lewis, T. C. VanCott, G. Stiegler, H. Katinger, M. Seaman, K. Beaudry, D. H. Barouch, B. Korioth-Schmitz, G. Krivulka, et al. 2003. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77:10348.
16. VanCott, T. C., R. W. Kaminski, J. R. Mascola, V. S. Kalyanaraman, N. M. Wassef, C. R. Alving, T. J. Ulrich, G. H. Lowell, and D. L. Birx. 1998. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160:2000.
17. Lundholm, P., Y. Asakura, J. Hinkula, E. Lucht, and B. Wahren. 1999. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17:2036.
18. Mazzoli, S., L. Lopalco, A. Salvi, D. Trabattoni, S. Lo Caputo, F. Semplici, M. Biasin, C. Bl, A. Cosma, C. Pastori, et al. 1999. Human immunodeficiency virus HIV-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J. Infect. Dis. 180:871.
19. Devito, C., J. Hinkula, R. Kaul, L. Lopalco, J. J. Bwayo, F. Plummer, M. Clerici, and K. Broliden. 2000. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14:1917.
20. Devito, C., J. Hinkula, R. Kaul, J. Kimani, P. Kiama, L. Lopalco, C. Barrass, S. Picconi, D. Trabattoni, J. J. Bwayo, et al. 2002. Cross-clade HIV-1 specific neutralizing IgA in mucosal and systemic compartments of HIV-1 exposed, persistently seronegative subjects. J. AIDS 30:413.
21. Devito, C., K. Broliden, R. Kaul, L. Svensson, K. Johansen, P. Kiama, J. Kimani, L. Lopalco, P. Stefania, J. J. Bwayo, et al. 2000. Mucosal and plasma IgA from HIV-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165:5170.
22. Clerici, M., C. Barassi, C. Devito, C. Pastori, S. Piconi, R. Longhi, J. Hinkula, K. Broliden, and L. Lopalco. 2002, Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41. AIDS 16:1731.
23. Lopalco, L., C. Barassi, C. Pastori, R. Longhi, S. E. Burastero, G. Tambussi, F. Mazotta, A. Lazzarin, M. Clerici, and A. G. Siccardi. 2000. CCR5-reactive antibodies in seronegative partners of HIV-seronegative individuals down-modulate surface CCR5 in vivo and neutralize infectivity of R5 strains of HIV in vitro. J. Immunol. 164:3426.
24. De Wolf, F., E. Hogervorst, J. Goudsmit, E. M. Fenyö, H. Rübsamen-Waigmann, H. Holmes, B. Galvao-Castro, E. Karita, C. Wasi, S. D. Sempala, et al. 1994. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristic. AIDS Res. Hum. Retroviruses 10:1387.
25. Schröder, U., S. B. Svenson. 1999. Nasal and parenteral immunizations with diphteria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 17:2096.
26. Asakura, Y., P. Lundholm, A. Kjerrström, R. Benthin, E. Lucht, J. Fukushima, K. Okuda, S. Schwartz, B. Wahren, and J. Hinkula. 1999. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. J. Biol. Chem. 380:375.
27. Sällberg, M., U. Ruden, L. O. Magnius, E. Norrby, and B. Wahren. 1991. Rapid "tea-bag" peptide synthesis using 9- fluorenylmetoxycarbonil (Fmoc) protected amino acids. Immunol. Lett. 30:59.
28. Bukawa, H., K. Sekigawa, K. Hamajima, J. Fukushima, Y. Yamada, H. Kiyono, and K. Okuda. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:681.
29. Åkerblom, L., J. Hinkula, P.-A. Broliden, B. Makitalo, T. Fridberger, J. Rosen, M. Villacres-Eriksson, B. Morein, and B. Wahren. 1990. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 4:953.
30. Devito, C., M. Levi, K. Broliden, and J. Hinkula. 2000. Mapping of B-cell epitopes in rabbits immunized with gag antigens for the production of HIV-1 gag capture ELISA reagents J. Immunol. Methods 238:69.
31. Mantis, N. J., P. A. Kozlowski, D. W. Mielcarz, W. Weissenhorn, and M. R. Neutra. 2001. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1 specific serum IgG and secretory IgA antibodies. Vaccine 19:3990.
32. LaCasse, R. A., K. E. Follis, M. Trahey, J. D. Scarborough, D. R. Littman, and J. H. Nunberg. 1999. Fusion-component vaccines: broad neutralization of primary isolates of HIV. Science 283:357.
33. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657.
34. Wild, C., T. Oas, C. McDanal, D. Bolognesi, T. A. Mathews. 1992. Synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89:10537.
35. Bomsel, M., M. Heyman, H. Hocini, S. Lagaye, L. Belec, C. Dupont, and C. Desgranges. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein IgA or IgM. Immunity 9:277.
36. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95:1709.
37. Murphey-Corb, M., L. A. Wilson, A. M. Trichel, D. E. Roberts, K. Xu, S. Ohkawa, B. Woodson, R. Bohm, and J. Blanchard. 1999. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162:540.
38. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 12:2072.
39. Staats, H. F., C. P. Bradney, W. M. Gwinn, S. S. Jackson, G. D., Sempowski, H.-X. Liao, N. L. Letvin, and B. F. Haynes. 2001. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167:5386.
40. Lee, B., M. Sharron, C. Blanpain, B. J. Doranz, J. Vakili, P. Setoh, E. Berg, G. Liu, H. R. Guy, S. R. Durrel, et al. 1999. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:9617.
41. Zuber, B., J. Hinkula, D. Vödrös, P. Lundholm, C. Nilsson, A. Mörner, M. Levi, R. Benthin, and B. Wahren. 2001. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 278:400.
42. Lehner, T., C. Doyle, Y. Wang, K. Babaahmady, T. Whittall, L. Tao, L. Bergmeier, and C. Kelly. 2001. Immunogeniticy of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency virus or HIV infectivity. J. Immunol. 166:7446.
43. Beddows, S., Louisirirotchanakul, R. Cheingsong-Popov, P. J. Easterbrook, P. Simmonds, and J. Weber. 1998. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J. Gen. Virol. 79:77.
44. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006.
45. Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS 11-S87.
46. Dong, X.-N., Y. Xiao, M. P. Dierich, and Y.-H. Chen. 2001. N- and C-domains of HIV-1 gp41: mutations, structure and functions. Immunol. Lett. 75:215.
47. Conley, A. J., P. Conrad, S. Bondy, C. A. Dolan, J. Hannah, W. J. Leanza, S. Marburg, M. Rivetna, V. K. Rusiecki, E. E. Sugg, et al. 1994. Immunogenecity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 12:445.
48. Alfsen, A., P. Iniguez, E. Bouguyon, and M. Bomsel. 2001. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166:6257.
49. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, et al. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728.
50. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. Barbas III, D. R. Burton, and D. D. Ho. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609.
51. Calarota, S., M. Jansson, M. Levi, K. Broliden, O. Libonatti, H. Wigzell, and B. Wahren. 1996. Immunodominant glycoprotein 41 epitope identified by sero-reactivity in HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses 12:705.
52. Kaneko, H., I. Bednarek, A. Wierzbicki, I. Kiszka, M. Dmochowski, T. J. Wasik, Y. Kaneko, and D. Kozbor. 2000. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267:8.
53. + responses. J. Clin. Invest. 107:341.
54. Margolis, H. S. 1993. Prevention of acute and chronic liver disease through immunizations: hepatitis B and beyond. J. Infect. Dis. 168:9.
55. Mainwright, R. B., B. J. McMahon, and L. S. Bulkow. 1989. Duration of immunogenecity and efficacy of hepatitis B in a Yupik Eskimo population. JAMA 261:2362.
56. West, D. J., and G. B. Calandra. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1:1019.
57. Mittrucker, H. W., B. Raupach, A. Kohler, and S. H. Kaufmann. 2000. Cutting edge: role of B lymphocytes in protective immunity against Salmonella typhymurium infection. J. Immunol. 164:1648.
58. Yang, X., and R. C. Brunham. 1998. Gene knockout B-cell-deficient mice demonstrate that B-cells play an important role in the initiation of T-cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol. 161:1439.
59. Moore, J. P., and A. Trkola. 1997. HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res. Hum. Retroviruses 13:733.
60. Ruprecht, R. M., R. Hofmann-Lehmann, B. A. Smith-Franklin, R. A. Rasmussen, V. Liska, J. Vlasak, W. Xu, T. W. Baba, A. L. Chenine, L. A. Cavacini, et al. 2001. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8:350.
61. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehuni, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200.